D Young & Co highly recommended by IAM Patent 1000

This good news from IAM Patent 1000 means that we continue to be ranked as a top tier UK IP firm by all the UK directories (Legal 500, Chambers UK, IP Stars, IAM Patent 1000 and WTR 1000).

Thank you to our clients and associate peers for your continued support and feedback to the researchers.

IAM Patent 1000 has written the following:

"Storied IP shop D Young & Co enjoyed a red-letter year in 2016: it celebrated 125 years in business and opened a new base in Munich to assist its burgeoning European efforts on both sides of the contentious/non-contentious divide. Its squad of technically astute professionals makes light work of all prosecution matters, while its chemistry, biotechnology and pharmaceutical group boasts particular proficiency in oppositions before the EPO.

Teva is among the high-profile pharmaceutical companies that have recently benefited from the set’s expertise in this area, with Neil Nachshen skilfully ensuring that the patent protecting the dosing regimen for its Copaxone product was upheld."

With over 20 years’ experience, Charles Harding is also a resolute defender of clients’ interests in life sciences oppositions and appeals.

Those seeking counsel on SPCs need look no further than Kirk Gallagher and Garreth Duncan. Gallagher is a pharmaceuticals and nutrition ace; while patrons “marvel at the quality and cost effectiveness” of the services provided by the “eminently qualified” Duncan.

A “trusted partner who can be relied upon for his technical expertise”, IAM Patent 1000 debutant Simon O’Brien is “a pleasure to work with – he seamlessly anticipates clients’ needs and consistently meets tight deadlines”.

Another distinguished member of the chemistry corps, Aylsa Williams leaves no stone unturned in the pursuit of international portfolio management perfection.

Captaining the firm’s mechanical practice, Anthony Albutt proves the set’s EPO opposition expertise is by no means limited to the life sciences.

A keystone of the firm’s relationship with Sony Mobile Communications Group, Jonathan Jackson is an electronics and IT whizz.

Ian Starr and Richard Willoughby are standout practitioners on the dispute resolution side. Starr brings deep insight into the pharmaceutical, fast-moving consumer goods and broadcasting markets to the table; while the UPC-savvy Willoughby has been juggling an array of contentious briefs, including the successful representation of Takeda in a case relating to SPCs based on its Alogliptin drug."